Maternal and neonatal outcomes after benzodiazepine and benzodiazepine
agonist exposure during pregnancy in women with mental disorders
Abstract
Abstract Objective To compare the gestational age of neonates in utero
exposed to benzodiazepines (BDZs) with none exposed controls. Secondary
objectives were; birth weight, presence of congenital malformations,
APGAR score, and the need for > 3 months (prolonged)
maternal psychiatric care. Study design A retrospective cohort study of
women and neonates from 2013 to 2021 with univariate and multivariable
analysis to study the associations between BDZs exposure and gestational
age compared to non-exposed women with mental health problems. Results
We found that BDZ exposure was associated with a lower gestational age
of -3.2 days (95% CI -5.8 , -0.53 days). Women in the exposed group had
an increased risk of psychiatric care (adjusted OR 2.511 (95% CI 1.675
– 3.782), p < 0.001). Conclusion We found that in utero BDZ
exposure was independently associated with a significantly lower
gestational age of the neonates and prolonged psychiatric care of their
mothers.